| scholarly article | Q13442814 |
| P356 | DOI | 10.1001/ARCHOPHT.121.11.1621 |
| P8608 | Fatcat ID | release_sxfe5usitrbu5kvb7mt2jja4jq |
| P932 | PMC publication ID | 1473209 |
| P698 | PubMed publication ID | 14609922 |
| P5875 | ResearchGate publication ID | 9015506 |
| P50 | author | Age-Related Eye Disease Study Research Group | Q83234373 |
| Neil M. Bressler | Q112187433 | ||
| Susan B Bressler | Q114739669 | ||
| P2093 | author name string | Ronald Klein | |
| David S Friedman | |||
| Frederick L Ferris | |||
| Johanna M Seddon | |||
| Anne S Lindblad | |||
| Nathan G Congdon | |||
| Roy C Milton | |||
| P2860 | cites work | A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8 | Q24544001 |
| Racial differences in the prevalence of age-related macular degeneration: the Baltimore Eye Survey | Q43587787 | ||
| Prevalence of age-related maculopathy. The Beaver Dam Eye Study | Q68207448 | ||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | public health | Q189603 |
| eye disease | Q3041498 | ||
| P304 | page(s) | 1621-1624 | |
| P577 | publication date | 2003-11-01 | |
| P1433 | published in | JAMA Ophthalmology | Q4787301 |
| P1476 | title | Potential public health impact of Age-Related Eye Disease Study results: AREDS report no. 11. | |
| P478 | volume | 121 |
| Q55470390 | A Discussion of Commercially Available Intra-ocular Telescopic Implants for Patients with Age-Related Macular Degeneration. |
| Q33235813 | A preliminary benefit-risk assessment of verteporfin in age-related macular degeneration |
| Q37289866 | A systematic review on the effect of bevacizumab in exudative age-related macular degeneration. |
| Q34991275 | Activation of Rap1 inhibits NADPH oxidase-dependent ROS generation in retinal pigment epithelium and reduces choroidal neovascularization |
| Q58588312 | Advanced glycation end products-related modulation of cathepsin L and NF-κB signalling effectors in retinal pigment epithelium lead to augmented response to TNFα |
| Q59055823 | Age-Related Macular Degeneration: Pathogenesis, Genetic Background, and the Role of Nutritional Supplements |
| Q25257145 | Age-related eye diseases: an emerging challenge for public health professionals |
| Q82698020 | Age-related macular degeneration |
| Q35890774 | Age-related macular degeneration: armed against ARMD. |
| Q47123727 | An Induced Pluripotent Stem Cell Patient Specific Model of Complement Factor H (Y402H) Polymorphism Displays Characteristic Features of Age-Related Macular Degeneration and Indicates a Beneficial Role for UV Light Exposure. |
| Q33831469 | Anti-inflammatory and antiangiogenic effects of nanoparticle-mediated delivery of a natural angiogenic inhibitor |
| Q24201127 | Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases |
| Q24242944 | Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases |
| Q34402842 | Assessment of targeting accuracy of a low-energy stereotactic radiosurgery treatment for age-related macular degeneration |
| Q37924077 | Association between high-risk disease loci and response to anti-vascular endothelial growth factor treatment for wet age-related macular degeneration |
| Q57539245 | Association of the HTRA1 gene variant with age-related macular degeneration in the Japanese population |
| Q47663159 | Automated Grading of Age-Related Macular Degeneration From Color Fundus Images Using Deep Convolutional Neural Networks. |
| Q92266156 | Automated detection and classification of early AMD biomarkers using deep learning |
| Q36348003 | Automated segmentation of geographic atrophy of the retinal epithelium via random forests in AREDS color fundus images |
| Q51221283 | Autophagy and KRT8/keratin 8 protect degeneration of retinal pigment epithelium under oxidative stress. |
| Q28294611 | Bevacizumab vs ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trial |
| Q57052936 | Bioactive Lipids and Pathological Retinal Angiogenesis |
| Q35140894 | CFH, VEGF, and PEDF genotypes and the response to intravitreous injection of bevacizumab for the treatment of age-related macular degeneration |
| Q42268901 | Comparative study of 1+PRN ranibizumab versus bevacizumab in the clinical setting. |
| Q45948597 | Comparing humans and deep learning performance for grading AMD: A study in using universal deep features and transfer learning for automated AMD analysis. |
| Q51743500 | Comparing outcomes in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration treated with two different doses of primary intravitreal bevacizumab: results of the Pan-American Collaborative Retina Study Gro |
| Q50495606 | Comparison of different treatment intervals between bevacizumab injection and photodynamic therapy in combined therapy for age-related macular degeneration. |
| Q33901283 | Comparison of long-acting bevacizumab formulations in the treatment of choroidal neovascularization in a rat model. |
| Q36938286 | Complement factor H and LOC387715/ARMS2/HTRA1 variant's frequencies and phenotypic associations in neovascular age-related macular degeneration, a pilot study |
| Q84649749 | Complementary and Alternative Medicines: Clinical Pearls for Commonly Used Dietary Supplements |
| Q35027522 | Copy number variations in candidate genes in neovascular age-related macular degeneration |
| Q38611218 | Cost-effectiveness of age-related macular degeneration study supplements in the UK: combined trial and real-world outcomes data |
| Q83869000 | Early visual impacts of optical coherence tomographic parameters in patients with age-related macular degeneration following the first versus repeated ranibizumab injection |
| Q33260828 | Effect of systemic bevacizumab therapy on retinal pigment epithelial detachment |
| Q33825687 | Estimated cases of blindness and visual impairment from neovascular age-related macular degeneration avoided in Australia by ranibizumab treatment |
| Q36167163 | Genetic analysis of simultaneous geographic atrophy and choroidal neovascularization |
| Q57176321 | Gout and the risk of age-related macular degeneration in the elderly |
| Q33213550 | Guidelines for interpreting retinal photographs and coding findings in the Submacular Surgery Trials (SST): SST report no. 8 |
| Q42236754 | High Dose Intravitreal Bevacizumab for Refractory Pigment Epithelial Detachment in Age-related Macular Degeneration |
| Q34650775 | Identification and metabolic transformations of carotenoids in ocular tissues of the Japanese quail Coturnix japonica |
| Q44924511 | Impact of visual impairment on service and device use by individuals with age-related macular degeneration (AMD). |
| Q34510579 | Interventions for Age-Related Macular Degeneration: Are Practice Guidelines Based on Systematic Reviews? |
| Q46377186 | Intraocular Properties of a Repository Urokinase Receptor Antagonist Å36 Peptide in Rabbits |
| Q39391488 | Intravitreal docosahexaenoic acid in a rabbit model: preclinical safety assessment |
| Q34160687 | Intravitreal injection of ranibizumab using a pro re nata regimen for age-related macular degeneration and vision-related quality of life |
| Q32125469 | LOC387715/HTRA1 gene polymorphisms and susceptibility to age-related macular degeneration: A HuGE review and meta-analysis |
| Q33216816 | Laser prophylaxis for age-related macular degeneration |
| Q35766506 | Long-term (60-month) results for the implantable miniature telescope: efficacy and safety outcomes stratified by age in patients with end-stage age-related macular degeneration. |
| Q86857727 | Long-term outcome of intravitreal pegaptanib sodium as maintenance therapy in Japanese patients with neovascular age-related macular degeneration |
| Q58715760 | Low incidence of choroidal neovascularization following subthreshold diode micropulse laser (SDM) in high-risk AMD |
| Q47995257 | Maintenance therapy with pegaptanib sodium for neovascular age-related macular degeneration: an exploratory study in Japanese patients (LEVEL-J study). |
| Q30855748 | Microfluidic co-cultures of retinal pigment epithelial cells and vascular endothelial cells to investigate choroidal angiogenesis. |
| Q37273740 | Molecular pathology of age-related macular degeneration |
| Q38174408 | Nature and nurture- genes and environment- predict onset and progression of macular degeneration. |
| Q33796324 | Nutritional manipulation of primate retinas, V: effects of lutein, zeaxanthin, and n-3 fatty acids on retinal sensitivity to blue-light-induced damage |
| Q37543563 | Ocular Risk Factors for Exudative AMD: A Novel Semiautomated Grading System. |
| Q36951800 | Overview of progress in the epidemiology of age-related macular degeneration |
| Q37402200 | Oxidized phospholipids in the macula increase with age and in eyes with age-related macular degeneration |
| Q37626352 | Parainflammation associated with advanced glycation endproduct stimulation of RPE in vitro: implications for age-related degenerative diseases of the eye. |
| Q36918766 | Pegaptanib in the treatment of wet, age-related macular degeneration |
| Q36201593 | Pegaptanib: in exudative age-related macular degeneration |
| Q99711914 | Plasma Biomarkers of Reticular Pseudodrusen and the Risk of Progression to Advanced Age-Related Macular Degeneration |
| Q35746909 | Potential role of lampalizumab for treatment of geographic atrophy |
| Q52658281 | Predictors of 1-year visual outcome in OCT analysis comparing ranibizumab monotherapy versus combination therapy with PDT in exsudative age-related macular degeneration. |
| Q35557353 | Progress and perspectives on the role of RPE cell inflammatory responses in the development of age-related macular degeneration |
| Q52866840 | Proposal of a simple optical coherence tomography-based scoring system for progression of age-related macular degeneration. |
| Q35645072 | Protective effect of paeoniflorin against oxidative stress in human retinal pigment epithelium in vitro |
| Q37239923 | Proteomics-based identification and validation of novel plasma biomarkers phospholipid transfer protein and mannan-binding lectin serine protease-1 in age-related macular degeneration |
| Q55054391 | Qualitative assessment of online information about age-related macular degeneration available in Portuguese. |
| Q35544176 | Quantitative Analysis of Segmented Fluorescein Angiography Images for the Follow-up of Choroidal Neovascular Membrane |
| Q43141355 | Quantitative optical coherence tomography findings in various subtypes of neovascular age-related macular degeneration |
| Q58593072 | Quantitative proteomic analysis of aqueous humor from patients with drusen and reticular pseudodrusen in age-related macular degeneration |
| Q33402860 | Quantitative subanalysis of cystoid spaces and outer nuclear layer using optical coherence tomography in age-related macular degeneration |
| Q37169291 | Quantitative subanalysis of optical coherence tomography after treatment with ranibizumab for neovascular age-related macular degeneration. |
| Q33317961 | Recombinant anti-vascular endothelial growth factor fusion protein efficiently suppresses choridal neovasularization in monkeys |
| Q34328499 | Resource utilization and costs of age-related macular degeneration. |
| Q54542940 | Response to anti-VEGF therapy in patients with subretinal fluid and pigment epithelial detachment on spectral-domain optical coherence tomography. |
| Q24554181 | Risk factors for the incidence of Advanced Age-Related Macular Degeneration in the Age-Related Eye Disease Study (AREDS) AREDS report no. 19 |
| Q33492369 | Role of pegaptanib sodium in the treatment of neovascular age-related macular degeneration |
| Q84607146 | Serum Inflammatory Factors in Patients with Idiopathic Choroidal Neovascularization |
| Q27008066 | Shanghai eye treatment outbreak: bevacizumab therapy for AMD in China |
| Q50967704 | Short-term effects of intravitreal ranibizumab and bevacizumab administration on 24-h ambulatory blood pressure monitoring recordings in normotensive patients with age-related macular degeneration. |
| Q35230959 | Smoking, antioxidant supplementation and dietary intakes among older adults with age-related macular degeneration over 10 years |
| Q28487616 | Structural characterization of a recombinant fusion protein by instrumental analysis and molecular modeling |
| Q84912301 | Subjective perception versus objective outcome after intravitreal ranibizumab for exudative AMD |
| Q36350410 | Suggestive association between PLA2G12A single nucleotide polymorphism rs2285714 and response to anti-vascular endothelial growth factor therapy in patients with exudative age-related macular degeneration. |
| Q34522738 | Summary results and recommendations from the age-related eye disease study |
| Q34081858 | Surgery for hemorrhagic choroidal neovascular lesions of age-related macular degeneration: ophthalmic findings: SST report no. 13. |
| Q34081805 | Surgery for hemorrhagic choroidal neovascular lesions of age-related macular degeneration: quality-of-life findings: SST report no. 14 |
| Q89454097 | Systemic Disease and Long-term Intraocular Pressure Mean, Peak, and Variability in Nonglaucomatous Eyes |
| Q37406558 | Tachyphylaxis after intravitreal bevacizumab for exudative age-related macular degeneration |
| Q35716443 | The Clinical Effectiveness and Cost-Effectiveness of Screening for Age-Related Macular Degeneration in Japan: A Markov Modeling Study |
| Q37678798 | The molecular genetic basis of age-related macular degeneration: an overview |
| Q33375953 | The pharmacology study of a new recombinant human VEGF receptor-fc fusion protein on experimental choroidal neovascularization |
| Q46755007 | The role of Stratus OCT in anti-VEGF therapy. Qualitative and quantitative assessment of neovascular AMD |
| Q35711457 | Treatment Frequency and Dosing Interval of Ranibizumab and Aflibercept for Neovascular Age-Related Macular Degeneration in Routine Clinical Practice in the USA |
| Q36659533 | Two Different Doses of Intravitreal Bevacizumab for Treatment of Choroidal Neovascularization Associated with Age-related Macular Degeneration |
| Q91640890 | Use of Deep Learning for Detailed Severity Characterization and Estimation of 5-Year Risk Among Patients With Age-Related Macular Degeneration |
| Q40287117 | Visual outcomes of age-related macular degeneration patients undergoing intravitreal ranibizumab monotherapy in an urban population. |
| Q34468393 | Visual prosthetic device for bilateral end-stage macular degeneration |
Search more.